Diabetic Nephropathy: Causative and Protective factors

Liang Zhou; Guanjing Zhang; Zhiyan Xu; Khrystyna Pronyuk; Xingming Chen

Authors

Liang Zhou
Guanjing Zhang
Zhiyan Xu
Khrystyna Pronyuk
Xingming Chen

Keywords:

diabetic nephropathy, causative factor, protective factor, protein kinase c, connective tissue growth factor, nuclear factor kappa b, osteopontin, rea

Abstract

Diabetic nephropathy (DN) is the major cause of chronic kidney disease (CKD) which normally leads to end stage renal disease (ESRD) or dialysis. Despite vigorous management including treatment of hypertension, glyceamic control and the utilization of inhibitors of renin angiotensin system (RAS), a significant proportion of diabetic patients still develop CKD and progress to ESRD. Advances in understanding of the pathogenesis and pathology of DN have made it clear that DN occurs as a result of imbalance between causative factors and endogenous protective factors. To emphasize this concept, this review will focus on some of the current knowledge concerning both causative and endogenous protective factors of DN.

Downloads

How to Cite

Diabetic Nephropathy: Causative and Protective factors. (2015). Global Journal of Medical Research, 15(14), 17-26. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

H. Ha, I. Hwang, J. Park, H. Lee (2008) Role of reactive oxygen species in the pathogenesis of diabetic nephropathy.

International Diabetes Federation (2014) IDF Diabetes Atlas Update Poster, 6th ed.

A. Sheridan, ;. Arya, S. Aggarwal, H. Yadav (2006) Molecular mechanisms underlying diabetic nephropathy. (8), 24-29.

G. Soldatos, M. Cooper (2008) Diabetic nephropathy: Important pathophysiologic mechanisms. 82, S75-S79. https://doi.org/10.1016/j.diabres.2008.09.042

M. Daroux, G. Prevost, H. Maillard-Lefebvre, C. Gaxatte, V. D'Agati, A. Schmidt, E. Boulanger, non-diabetic Diabetes (2010) Advanced glycation end-products: Implications for diabetic and non-diabetic nephropathies. 36(1), 1-10. https://doi.org/10.1016/j.diabet.2009.06.005

Pitchai Balakumar, Mandeep Arora, Subrahmanya Ganti, Jayarami Reddy, Manjeet Singh (2009) Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. 60(1), 24-32. https://doi.org/10.1016/j.phrs.2009.02.002

Mandeep Arora, Umesh Singh (2013) Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update. 58(4), 259-271. https://doi.org/10.1016/j.vph.2013.01.001

Christian Rask-Madsen, George King (2013) Vascular Complications of Diabetes: Mechanisms of Injury and Protective Factors. 17(1), 20-33. https://doi.org/10.1016/j.cmet.2012.11.012

Caroline Magri, Stephen Fava (2009) The role of tubular injury in diabetic nephropathy. 20(6), 551-555. https://doi.org/10.1016/j.ejim.2008.12.012

Claire Hills, Paul Squires (2011) The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. 22, 131-139. https://doi.org/10.1016/j.cytogfr.2011.06.002

S. Chabroux, F. Canoui-Poitrine, S. Reffet, G. Joncour, E. Mordlon, C. Colin, C. Thivolet, but Diabetes (2010) Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. 36(2), 152-157. https://doi.org/10.1016/j.diabet.2009.11.003

T. K. Nowotny, Jung (2015) Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. 5(1), 194-222. https://doi.org/10.3390/biom5010194

N. Tanji, C. G.S. Markowitz, T. Kislinger, A. Taguchi, M. Pischetsrieder, D. Stern, A. Schmidt, V. D'Agati, Expression endproduces (2000) Expression of advanced glycation endproduces and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. 11, 1656-66.

D. Suzuki, M. Toyoda, N. Yamamoto, M. Miyauchi, M. Katoh, M. Kimura, M. Maruyama, M. Honma, T. Umezono, M. Yagame (2006) Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. 45, 435-41.

S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, S. Okuda (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. 17, 983-96.

Y. Yamamoto, T. I. Kato, H. Yonekura, S. Ohashi, Development (2001) Development and prevention of advanced diabetic nephropathy in RAGE overexpressing mice. 108, 261-8.

T. Soulis, M. Cooper, D. Vranes, R. Bucala, G. Jerums (1996) Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. 50, 627-34.

J. Forbes, V. Thallas, M. Thomas, H. Founds, W. Burns, G. Jerums, M. Cooper (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. 17(12), 1762-1784.

Y. (1995) Nishizuka Protein kinase C and lipid signaling for sustained cellular responses. 9, 484-496.

Semantee Bhattacharya, Prasenjit Manna, Ratan Gachhui, Parames Sil (2013) d-Saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling. 267(1), 16-29. https://doi.org/10.1016/j.taap.2012.12.005

R. Gilbert, S. Kim, K. Tuttle, G. Bakris, R. Toto, J. McGill (2007) Effect of Ruboxistaurin on Urinary Transforming Growth Factor-β in Patients With Diabetic Nephropathy and Type 2 Diabetes. 30, 995-996.

K. Tuttle, G. Bakris, R. Toto, K. J.B. McGill, P. Anderson (2005) The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. 28, 2686-2690.

Ye Song, Cai Li, Lu Cai (2004) Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. 76(1), 66-75. https://doi.org/10.1016/j.yexmp.2003.08.002

Weier Qi, Xinming Chen, Philip Poronnik, Carol Pollock (2008) Transforming growth factor-β/connective tissue growth factor axis in the kidney. 40(1), 9-13. https://doi.org/10.1016/j.biocel.2007.01.006

S. Twigg, M. Chen, A. Joly, S. Chakrapani, J. Tsubaki, H. Kim, Y. Oh, R. Rosenfeld Advanced Glycosylation End Products Up-Regulate Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein-Related Protein 2) in Human Fibroblasts: A Potential Mechanism for Expansion of Extracellular Matrix in Diabetes Mellitus*.

N. Wahab, B. Weston, R. Mason (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor Trk A. 16, 340-351.

H. Yokoi, M. Mukoyama, T. Nagae, K. Mori, T. Suganami, K. Sawai, T. Yoshioka, M. Koshikawa, T. Nishida, M. Takigawa, A. Sugawara, K. Nakao (2004) Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. 15, 1430-1440.

S. Adler, S. Schwartz, M. Williams, C. Arauz Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria.

J. Napetschnig, H. Wu (2013) Molecular basis of NF-κB signaling. 42, 443-468.

S. Mezzano, C. Aros, A. Droguett, M. Burgos, L. Ardiles, C. Flores, H. Schneider, M. Ruiz-Ortega, J. Egido (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. 19(10), 2505-2512.

W. Liu, X. Zhang, P. Liu, X. Shen, T. Lan, W. Li, Q. Jiang, X. Xie, H. Huang (2010) Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. 638, 150-155.

H. Ha, M. Yu, Y. j Role of High Glucose-Induced Nuclear Factor-κB Activation in Monocyte Chemoattractant Protein-1 Expression by Mesangial Cells.

B. Schrijvers, A. De Vriese, A. Flyvbjerg, hemodynamic, intracellular factors (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. 25(6), 971-1010.

T. Okado, Y. Terada, H. Tanaka, S. Inoshita, A. Nakao, S. Sasaki (2002) Smad7 mediates transforming growth factor-beta-induced apoptosis in mesangial cells. 62, 1178-86.

Raman Nagarajan, Feifei Chen, Wei Li, Eva Vig, Maureen Harrington, Harikrishna Nakshatri, Yan Chen (2000) Repression of transforming-growth-factor-β-mediated transcription by nuclear factor κB. 348(3), 591-596. https://doi.org/10.1042/bj3480591

J. Chiu, H. Farhangkhoee, S. Chakrabarti Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB.

M. Scatena, L. Liaw, C. Giachelli (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. 27, 2302-2309.

J. Heuer, M. Breyer (2010) Osteopontin in diabetic nephropathy: signpost or road?. 77, 565-6.

Susanne Nicholas, Joey Liu, Jason Kim, Yuelan Ren, Alan Collins, Lam Nguyen, Willa Hsueh (2010) Critical role for osteopontin in diabetic nephropathy. 77(7), 588-600. https://doi.org/10.1038/ki.2009.518

K. Susztak, E. Böttinger, A. Novetsky, Y. D. Liang, D. E. Ciccone, S. Dunn, P. McCue, K. Sharma (2004) Molecular Profiling of Diabetic Mouse Kidney Reveals Novel Genes Linked to Glomerular Disease. 53(3), 784-794. https://doi.org/10.2337/diabetes.53.3.784

J. Lorenzen, R. Shah, A. Biser, S. Staicu, T. Niranjan, A. Garcia, A. Gruenwald, D. Thomas, I. Shatat, K. Supe, R. Woroniecki, K. Susztak (2008) The role of osteopontin in the development of albuminuria. 19, 884-890.

N. Endlich, M. Sunohara, W. Nietfeld, E. Wolski, D. Schiwek, B. Kränzlin, N. Gretz, W. Kriz, H. Eickhoff, K. Endlich (2002) Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. 16, 1850-1852.

C. Sodhi, D. Battle, A. Sahai (2000) Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: role of PKC and p38 MAPK. 58, 691-700.

L. Zhang, S. Pang, B. Deng, L. Qian, J. J. Chen, L. J. Zheng, Yang, C. Zhang, Z. X. Chen, Y. Le (2012) High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-κB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. 44, 629-638.

J. Forbes, M. Coughlan (2008) Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes. (6), 1446-1454.

F. M.L. Brezniceanu, C. Wei, S. Tran, S. Sachetelli, S. Zhang, D. Guo, J. Filep, J. Ingelfinger, J. Chan, Catalase expression (2007) Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. 71, 912-923.

N. Kashihara, Y. Haruna, V. K. Kondeti, Y. S. Kanwar Oxidative Stress in Diabetic Nephropathy.

S. Jeong, S. Kim, K. T.H.Kwon, S.Y.Kim (2012) Schizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucose. 50, 1045-1053.

N. Park, S. Park, Y. Lim Long-term dietary antioxidant cocktail supplementation effectively reduces renal inflammation in diabetic mice.

B. Perkins, L. Ficociello, K. Silva (2003) Regression of microalbuminuria in type 1 diabetes. 348, 2285-93.

M. Tessier-Lavigne, C.S.Goodman (1996) The Molecular Biology of Axon Guidance. 274, 1123-1133.

S. Navankasattusas, K. Whitehead, A. Suli, L. Sorensen, A. Lim, et J. Zhao (2008) The netrin receptor UNC5B promotes angiogenesis in specific vascular beds. 135, 659-667.

WW, W. Wang, &. Reeves, Ramesh (2008) Netrin-1 and kidney injury. 1. Netrin-1 protects against ischemia-reperfusion injury of the kidney. 294(4), 739-747.

G. Ramesh (2012) Role of netrin-1 beyone the brain: from biomarker of tissue injury to therapy for inflammatory disease. 2(3), 202-208.

D. Zozulinska, Clinical Practice (2006) Type 2 diabetes mellitus as inflammatory disease. 74S, S12-S16.

R. Mohamed, C. Jayakumar, P. Ranganathan, V. Ganapahty, G. Ramesh (2012) Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice. 181.

E. Tak, D. Ridyard, A. Badulak, A. Giebler, U. Shabeka, T. Werner (2013) Protective role for netrin-1 during diabetic nephropathy. 91, 1071-1080.

Y. Su, H. Deng, M. Zhang, J. Long, Z. Peng (2012) Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin-mediated survival pathway by adenosine 5-Monophosphate-activated protein kinase. 44, 21-27.

N., Sweiss, K. Sharma (2013) Adiponectin effects on the kidney. 1-9.

Takashi Kadowaki, Toshimasa Yamauchi (2005) Adiponectin and Adiponectin Receptors. 26(3), 439-451. https://doi.org/10.1210/er.2005-0005

X. Fang, G. Sweeney (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. 34(5), 798-801. https://doi.org/10.1042/bst0340798

S. Nakamaki, H. Satoh, A. Kudoh, Y. Hayashi, H. Hirai, T. Watanabe (2011) Adiponectinreduces proteinuria in streptozotocin-induced diabetic Wistar rats. 236(5), 614-20.

K. Ohashi, H. Iwatani, S. Kihara (2007) Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. 27(9). https://doi.org/10.1161/atvbaha.107.147645

K. Sharma, S. Ramachandrarao, G. Qiu Adiponectin regulates albuminuria and podocyte function in mice.

R. Gilbert, P. Marsden, Activated C (2008) Activated protein C and diabetic nephropathy. 358(15), 1628-1630.

P. Gil-Bernabe, C. D'Alessandro-Gabazza, M. Toda, et D. Boveda Ruiz (2012) Exogenous activated protein C inhibits the progression of diabetic nephropathy. 10(3), 337-346.

K. Naruse, C. Rask-Madsen, S. N. Takahara, et K. Suzuma (2006) Activation of Vascular Protein Kinase C-β Inhibits Akt-Dependent Endothelial Nitric Oxide Synthase Function in Obesity-Associated Insulin Resistance. 55(3), 691-698. https://doi.org/10.2337/diabetes.55.03.06.db05-0771

K. Kuboki, Z. Jiang, N. Takahara, S. Ha (2000) et al, Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. 101(6), 676-681. https://doi.org/10.1161/01.cir.101.6.676

K. Tsuchiya, J. Tanaka, Y. Shuiqing, C. Welch, et R.A. Depinho (2012) FoxOs intergrate pleiotropic actions of insulin in vascular endothelium protect mice from atherosclerosis. 15, 372-381.

Corinna Hermann, Birgit Assmus, Carmen Urbich, Andreas Zeiher, Stefanie Dimmeler (2000) Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. 20(2), 402-409. https://doi.org/10.1161/01.atv.20.2.402

Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. 106, 1319-1331.

Mima, Y. Ohshiro, M. Kitada, et M. Matsumoto, obesity. international (2011) Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. 79(8), 883-896. https://doi.org/10.1038/ki.2010.526

G. Welsh, L. Hale, V. Eremina, M. Jeansson, Y. Maezawa (2010) Insulin Signaling to the Glomerular Podocyte Is Critical for Normal Kidney Function. 12(4), 329-340. https://doi.org/10.1016/j.cmet.2010.08.015